As vaccine technologies continue to expand, David Hage explores how analytical methods must evolve to meet growing demands for safety, quality, and activity testing
“And when one of these measles cases ends up in a low-immunization community, that's when the ember really has a chance to expand and become a wildfire.”
“And when one of these measles cases ends up in a low-immunization community, that's when the ember really has a chance to expand and become a wildfire.”
Phase 3 ENHANCE-1 results showed higher composite clinical cure and microbiologic response rates with cefepime-zidebactam vs meropenem in hospitalized adults with complicated urinary tract infection or acute pyelonephritis.